
Riccarda Granata

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9175333/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ghrelin. Molecular Metabolism, 2015, 4, 437-460.	6.5	810
2	Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. Journal of Cell Biology, 2002, 159, 1029-1037.	5.2	673
3	Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 4156-4161.	7.1	372
4	Acylated and Unacylated Ghrelin Promote Proliferation and Inhibit Apoptosis of Pancreatic β-Cells and Human Islets: Involvement of 3′,5′-Cyclic Adenosine Monophosphate/Protein Kinase A, Extracellular Signal-Regulated Kinase 1/2, and Phosphatidyl Inositol 3-Kinase/Akt Signaling. Endocrinology, 2007, 148, 512-529.	2.8	272
5	Does autophagy have a license to kill mammalian cells?. Cell Death and Differentiation, 2009, 16, 12-20.	11.2	231
6	Obestatin Promotes Survival of Pancreatic β-Cells and Human Islets and Induces Expression of Genes Involved in the Regulation of β-Cell Mass and Function. Diabetes, 2008, 57, 967-979.	0.6	173
7	Ghrelin and des-acyl ghrelin both inhibit isoproterenol-induced lipolysis in rat adipocytes via a non-type 1a growth hormone secretagogue receptor. European Journal of Pharmacology, 2004, 498, 27-35.	3.5	172
8	The IGF system. Acta Diabetologica, 2011, 48, 1-9.	2.5	154
9	Dual effects of IGFBPâ€3 on endothelial cell apoptosis and survival: Involvement of the sphingolipid signaling pathways. FASEB Journal, 2004, 18, 1456-1458.	0.5	116
10	Natural (ghrelin) and synthetic (hexarelin) GH secretagogues stimulate H9c2 cardiomyocyte cell proliferation. Journal of Endocrinology, 2002, 175, 201-209.	2.6	101
11	Heterogeneity of Ghrelin/Growth Hormone Secretagogue Receptors. Neuroendocrinology, 2007, 86, 147-164.	2.5	97
12	Insulin-like growth factor binding protein-3 induces angiogenesis through IGF-I- and SphK1-dependent mechanisms. Journal of Thrombosis and Haemostasis, 2007, 5, 835-845.	3.8	95
13	Unraveling the role of the ghrelin gene peptides in the endocrine pancreas. Journal of Molecular Endocrinology, 2010, 45, 107-118.	2.5	88
14	The ghrelin gene products and exendin-4 promote survival of human pancreatic islet endothelial cells in hyperglycaemic conditions, through phosphoinositide 3-kinase/Akt, extracellular signal-related kinase (ERK)1/2 and cAMP/protein kinase A (PKA) signalling pathways. Diabetologia, 2012, 55, 1058-1070.	6.3	83
15	Obestatin regulates adipocyte function and protects against dietâ€induced insulin resistance and inflammation. FASEB Journal, 2012, 26, 3393-3411.	0.5	79
16	Unacylated ghrelin and obestatin increase islet cell mass and prevent diabetes in streptozotocin-treated newborn rats. Journal of Molecular Endocrinology, 2010, 45, 9-17.	2.5	78
17	Unacylated Ghrelin Promotes Skeletal Muscle Regeneration Following Hindlimb Ischemia via SODâ€2–Mediated miRâ€221/222 Expression. Journal of the American Heart Association, 2013, 2, e000376.	3.7	78
18	Growth hormone-releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischaemia–reperfusion injury in rat heart. Cardiovascular Research, 2009, 83, 303-312.	3.8	75

#	Article	IF	CITATIONS
19	Unacylated Ghrelin Rescues Endothelial Progenitor Cell Function in Individuals With Type 2 Diabetes. Diabetes, 2010, 59, 1016-1025.	0.6	73
20	Unacylated Ghrelin Induces Oxidative Stress Resistance in a Glucose Intolerance and Peripheral Artery Disease Mouse Model by Restoring Endothelial Cell miR-126 Expression. Diabetes, 2015, 64, 1370-1382.	0.6	73
21	Metabolic effects of overnight continuous infusion of unacylated ghrelin in humans. European Journal of Endocrinology, 2012, 166, 911-916.	3.7	70
22	Somatostatin, cortistatin and their receptors in tumours. Molecular and Cellular Endocrinology, 2008, 286, 219-229.	3.2	61
23	Proliferative and Protective Effects of Growth Hormone Secretagogues on Adult Rat Hippocampal Progenitor Cells. Endocrinology, 2008, 149, 2191-2199.	2.8	58
24	Adipocyte-derived extracellular vesicles regulate survival and function of pancreatic \hat{I}^2 cells. JCI Insight, 2021, 6, .	5.0	55
25	Cardiovascular actions of the ghrelin gene-derived peptides and growth hormone-releasing hormone. Experimental Biology and Medicine, 2011, 236, 505-514.	2.4	53
26	Unacylated as well as acylated ghrelin promotes cell survival and inhibit apoptosis in HIT-T15 pancreatic Î ² -cells. Journal of Endocrinological Investigation, 2006, 29, RC19-RC22.	3.3	51
27	Actions and Potential Therapeutic Applications of Growth Hormone–Releasing Hormone Agonists. Endocrinology, 2019, 160, 1600-1612.	2.8	51
28	Endogenous Cardioprotective Agents: Role in Pre and Postconditioning. Current Drug Targets, 2015, 16, 843-867.	2.1	47
29	Des-Acyl Ghrelin Fragments and Analogues Promote Survival of Pancreatic β-Cells and Human Pancreatic Islets and Prevent Diabetes in Streptozotocin-Treated Rats. Journal of Medicinal Chemistry, 2012, 55, 2585-2596.	6.4	46
30	RFamide Peptides 43RFa and 26RFa Both Promote Survival of Pancreatic Î ² -Cells and Human Pancreatic Islets but Exert Opposite Effects on Insulin Secretion. Diabetes, 2014, 63, 2380-2393.	0.6	44
31	Growth hormone-releasing hormone attenuates cardiac hypertrophy and improves heart function in pressure overload-induced heart failure. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 12033-12038.	7.1	44
32	Obestatin in human neuroendocrine tissues and tumours: expression and effect on tumour growth. Journal of Pathology, 2009, 218, 458-466.	4.5	42
33	GPR103b Functions in the Peripheral Regulation of Adipogenesis. Molecular Endocrinology, 2010, 24, 1615-1625.	3.7	37
34	Obestatin regulates cardiovascular function and promotes cardioprotection through the nitric oxide pathway. Journal of Cellular and Molecular Medicine, 2017, 21, 3670-3678.	3.6	37
35	The Arg–Pheâ€amide peptide 26RFa/glutamine RFâ€amide peptide and its receptor: IUPHAR Review 24. British Journal of Pharmacology, 2017, 174, 3573-3607.	5.4	36
36	Ghrelin in cardiovascular disease and atherogenesis. Molecular and Cellular Endocrinology, 2011, 340, 59-64.	3.2	35

#	Article	IF	CITATIONS
37	Growth Hormone-Releasing Peptide Hexarelin Reduces Neonatal Brain Injury and Alters Akt/Glycogen Synthase Kinase-3l² Phosphorylation. Endocrinology, 2005, 146, 4665-4672.	2.8	34
38	Acylated and unacylated ghrelin attenuate isoproterenol-induced lipolysis in isolated rat visceral adipocytes through activation of phosphoinositide 3-kinase γ and phosphodiesterase 3B. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2011, 1811, 386-396.	2.4	34
39	The continuous infusion of acylated ghrelin enhances growth hormone secretion and worsens glucose metabolism in humans. Journal of Endocrinological Investigation, 2008, 31, 788-794.	3.3	33
40	Somatostatin and somatostatin analogues reduce PDGF-induced endometrial cell proliferation and motility. Human Reproduction, 2012, 27, 2117-2129.	0.9	33
41	Obestatin: Is It Really Doing Something?. Frontiers of Hormone Research, 2014, 42, 175-185.	1.0	32
42	Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2226-2231.	7.1	29
43	GH-Releasing Hormone Induces Cardioprotection in Isolated Male Rat Heart via Activation of RISK and SAFE Pathways. Endocrinology, 2013, 154, 1624-1635.	2.8	28
44	Obestatin: A new metabolic player in the pancreas and white adipose tissue. IUBMB Life, 2013, 65, 976-982.	3.4	28
45	Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery. European Journal of Pharmacology, 2002, 448, 193-200.	3.5	26
46	The extremely low frequency electromagnetic stimulation selective for cancer cells elicits growth arrest through a metabolic shift. Biochimica Et Biophysica Acta - Molecular Cell Research, 2019, 1866, 1389-1397.	4.1	26
47	Endocrine and Metabolic Actions of Ghrelin. Endocrine Development, 2010, 17, 86-95.	1.3	24
48	Peripheral activities of growth hormone-releasing hormone. Journal of Endocrinological Investigation, 2016, 39, 721-727.	3.3	24
49	Antinflammatory, antioxidant, and behavioral effects induced by administration of growth hormone-releasing hormone analogs in mice. Scientific Reports, 2020, 10, 732.	3.3	24
50	Obestatin Enhances In Vitro Generation of Pancreatic Islets through Regulation of Developmental Pathways. PLoS ONE, 2013, 8, e64374.	2.5	23
51	Unacylated ghrelin prevents mitochondrial dysfunction in a model of ischemia/reperfusion liver injury. Cell Death Discovery, 2017, 3, 17077.	4.7	23
52	In vitro and in vivo stability and pharmacokinetic profile of unacylated ghrelin (UAG) analogues. European Journal of Pharmaceutical Sciences, 2012, 47, 625-635.	4.0	22
53	Pluripotent stem cells isolated from human amniotic fluid and differentiation into pancreatic β-cells. Journal of Endocrinological Investigation, 2009, 32, 873-876.	3.3	21
54	The Gut Hormone Ghrelin Partially Reverses Energy Substrate Metabolic Alterations in the Failing Heart. Circulation: Heart Failure, 2014, 7, 643-651.	3.9	21

#	Article	IF	CITATIONS
55	Obestatin promotes proliferation and survival of adult hippocampal progenitors and reduces amyloid-β-induced toxicity. Molecular and Cellular Endocrinology, 2016, 422, 18-30.	3.2	20
56	Insulin-Like Growth Factor I Levels and the Diagnosis of Adult Growth Hormone Deficiency. Hormone Research in Paediatrics, 2004, 62, 26-33.	1.8	19
57	Shortâ€ŧerm dehydroepiandrosterone treatment increases platelet cGMP production in elderly male subjects. Clinical Endocrinology, 2006, 64, 260-264.	2.4	19
58	The growth hormone–releasing hormone (GHRH) antagonist JV-1-36 inhibits proliferation and survival of human ectopic endometriotic stromal cells (ESCs) and the T HESC cell line. Fertility and Sterility, 2010, 94, 841-849.	1.0	19
59	GH-Releasing Hormone Promotes Survival and Prevents TNF-α-Induced Apoptosis and Atrophy in C2C12 Myotubes. Endocrinology, 2015, 156, 3239-3252.	2.8	19
60	Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, PI3K/Akt, GSK-3β signaling and inhibition of cellular prostatic acid phosphatase. Cancer Letters, 2019, 449, 252-262.	7.2	19
61	The Role of Obestatin in Glucose and Lipid Metabolism. Hormone and Metabolic Research, 2013, 45, 1002-1008.	1.5	17
62	The Mineralocorticoid Agonist Fludrocortisone Promotes Survival and Proliferation of Adult Hippocampal Progenitors. Frontiers in Endocrinology, 2016, 7, 66.	3.5	17
63	Ghrelin and Synthetic Growth Hormone Secretagogues are Cardioactive Molecules with Identities and Differences. Seminars in Vascular Medicine, 2004, 4, 107-114.	2.1	15
64	Neuroendocrine and metabolic activities of ghrelin gene products. Peptides, 2011, 32, 2323-2332.	2.4	15
65	Obestatin Plays an Opposite Role in the Regulation of Pituitary Somatotrope and Corticotrope Function in Female Primates and Male/Female Mice. Endocrinology, 2014, 155, 1407-1417.	2.8	15
66	Myocardial Insulin-like Growth Factor-1 and Insulin-like Growth Factor Binding Protein-3 Gene Expression in Failing Hearts Harvested From Patients Undergoing Cardiac Transplantation. Journal of Heart and Lung Transplantation, 2009, 28, 402-405.	0.6	12
67	Products of the Ghrelin Gene, the Pancreatic β-Cell and the Adipocyte. Endocrine Development, 2013, 25, 144-156.	1.3	12
68	Statins Directly Regulate Pituitary Cell Function and Exert Antitumor Effects in Pituitary Tumors. Neuroendocrinology, 2020, 110, 1028-1041.	2.5	12
69	Calcitriol Inhibits Viability and Proliferation in Human Malignant Pleural Mesothelioma Cells. Frontiers in Endocrinology, 2020, 11, 559586.	3.5	11
70	Circulating obestatin levels in normal and Type 2 diabetic subjects. Journal of Endocrinological Investigation, 2010, 33, 211-214.	3.3	10
71	Protective effects of growth hormone-releasing hormone analogs in DSS-induced colitis in mice. Scientific Reports, 2021, 11, 2530.	3.3	10
72	Pyroglutamylated RF-amide Peptide (QRFP) Gene Is Regulated by Metabolic Endotoxemia. Molecular Endocrinology, 2014, 28, 65-79.	3.7	9

#	Article	IF	CITATIONS
73	Role of Melatonin, Galanin, and RFamide Neuropeptides QRFP26 and QRFP43 in the Neuroendocrine Control of Pancreatic β-Cell Function. Frontiers in Endocrinology, 2017, 8, 143.	3.5	9
74	A Linear Fragment of Unacylated Chrelin (UAG6â^'13) Protects Against Myocardial Ischemia/Reperfusion Injury in Mice in a Growth Hormone Secretagogue Receptor-Independent Manner. Frontiers in Endocrinology, 2018, 9, 798.	3.5	9
75	H9c2 cardiac muscle cells express all somatostatin receptor subtypes. Journal of Endocrinological Investigation, 2004, 27, 24-27.	3.3	7
76	The IGF-I/IGFBP-3 system in gingival crevicular fluid and dependence on application of fixed force. Journal of Endocrinological Investigation, 2005, 28, 1009-1014.	3.3	7
77	Contribution of dendritic cells FcγRI and FcγRIII to cross-presentation of tumor cells opsonized with the anti-MHC class I monoclonal antibodies. Cancer Biology and Therapy, 2007, 6, 1932-1937.	3.4	7
78	QRFP-43 inhibits lipolysis by preventing ligand-induced complex formation between perilipin A, caveolin-1, the catalytic subunit of protein kinase and hormone-sensitive lipase in 3T3-L1 adipocytes. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 657-666.	2.4	7
79	Effects of growth hormone-releasing hormone receptor antagonist MIA-602Âin mice withÂemotional disorders: a potential treatment for PTSD. Molecular Psychiatry, 2021, 26, 7465-7474.	7.9	7
80	Antagonist of growth hormone-releasing hormone MIA-690 attenuates the progression and inhibits growth of colorectal cancer in mice. Biomedicine and Pharmacotherapy, 2022, 146, 112554.	5.6	7
81	IGFs and IGFBPs in Adult Growth Hormone Deficiency. , 2005, 9, 76-88.		5
82	Editorial: Neuroendocrine Control of Feeding Behavior. Frontiers in Endocrinology, 2019, 10, 399.	3.5	5
83	Growth hormone-releasing hormone antagonistic analog MIA-690 stimulates food intake in mice. Peptides, 2021, 142, 170582.	2.4	4
84	Antagonists of Growth Hormone-Releasing Hormone Inhibit the Growth of Pituitary Adenoma Cells by Hampering Oncogenic Pathways and Promoting Apoptotic Signaling. Cancers, 2021, 13, 3950.	3.7	4
85	Editorial: Pathophysiological Interrelationship Between Obesity, Metabolic Diseases, and Cancer. Frontiers in Oncology, 2021, 11, 755735.	2.8	3
86	Effect of digoxin on the somatotroph responsiveness to growth hormone-releasing hormone (GHRH) alone or combined with arginine in normal young volunteers. Clinical Endocrinology, 2001, 55, 755-758.	2.4	2
87	Growth hormone-releasing hormone (GHRH) antagonists increase the sensitivity to radiotherapy in lung cancer cells. Endocrine Abstracts, 0, , .	0.0	1
88	A New Role for GPR103b in the Peripheral Regulation of Adipogenesis. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3564-3564.	3.6	0
89	Physiological Roles of Des-Acyl Ghrelin. , 2012, , 267-275.		0
90	Azioni biologiche e metaboliche di obestatin, un peptide della famiglia del gene ghrelin. L Endocrinologo, 2013, 14, 239-242.	0.0	0

#	Article	IF	CITATIONS
91	SAT-603 Growth Hormone-Releasing Hormone (GHRH) Antagonists Stimulate Feeding in Mice. Journal of the Endocrine Society, 2020, 4, .	0.2	0
92	Antitumor effects of growth hormone-releasing hormone (GHRH) antagonists in ACTH–and GH-secreting pituitary neuroendocrine tumor (PitNETs) cell lines. Endocrine Abstracts, 0, , .	0.0	0
93	Role of Extracellular vesicles in the crosstalk between adipocytes and pancreatic beta-cells. Endocrine Abstracts, 0, , .	0.0	0
94	Growth hormone-releasing hormone (GHRH) antagonists, MIA-602 and MIA-690, inhibit survival and proliferation of human pleural mesothelioma cells. Endocrine Abstracts, 0, , .	0.0	0
95	Peripheral activities of growth hormone-releasing hormone (GHRH). Endocrine Abstracts, 0, , .	0.0	0
96	Antitumor effects of growth hormone-releasing hormone (GHRH) antagonists in ACTH and GH-secreting pituitary adenoma cell lines. Endocrine Abstracts, 0, , .	0.0	0
97	QRFP receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	0
98	Growth hormone-releasing hormone (GHRH) promotes survival and proliferation of neural stem cells and reduces amyloid-1²-induced toxicity. Endocrine Abstracts, 0, , .	0.0	0
99	Antitumor effects of growth hormone-releasing hormone (CHRH) antagonists in ACTH- and CH-secreting pituitary neuroendocrine tumor cell lines. Endocrine Abstracts, 0, , .	0.0	Ο